Literature DB >> 14754959

Management of a severe carbamazepine overdose using albumin-enhanced continuous venovenous hemodialysis.

David J Askenazi1, Stuart L Goldstein, I-Fen Chang, Ewa Elenberg, Daniel I Feig.   

Abstract

Carbamazepine intoxication is common in the pediatric population. Highly protein-bound, carbamazepine is not removed efficiently through conventional hemodialysis. We describe the use of albumin-enhanced continuous venovenous hemodialysis (CVVHD) in a 10-year-old girl who developed coma and respiratory depression due to an intentional carbamazepine overdose (peak drug level of 44.8 microg/ml; therapeutic range: 8-12 microg/ml). Without intervention, the half-life of drug elimination is 25 to 60 hours in patients who are naive to carbamazepine and 12 to 20 hours in children on chronic carbamazepine therapy. In contrast, with albumin-enhanced CVVHD, we observed a half-life of 7 to 8 hours. The patient recovered rapidly and was discharged from hospital <4 days from the time of ingestion with no complications or neurologic impairment. Because the cost-benefit analysis was also favorable relative to other therapeutic options, albumin-enhanced CVVHD may be the optimal treatment of toxic-level ingestion of carbamazepine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14754959     DOI: 10.1542/peds.113.2.406

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  15 in total

1.  Renal replacement therapy in the management of intoxications in children: recommendations from the Pediatric Continuous Renal Replacement Therapy (PCRRT) workgroup.

Authors:  Rupesh Raina; Manpreet K Grewal; Martha Blackford; Jordan M Symons; Michael J G Somers; Christoph Licht; Rajit K Basu; Sidharth Kumar Sethi; Deepa Chand; Gaurav Kapur; Mignon McCulloch; Arvind Bagga; Vinod Krishnappa; Hui-Kim Yap; Marcelo de Sousa Tavares; Timothy E Bunchman; Michelle Bestic; Bradley A Warady; Maria Díaz-González de Ferris
Journal:  Pediatr Nephrol       Date:  2019-08-24       Impact factor: 3.714

2.  Enhanced clearance of carbamazepine using albumin-containing dialysate during CVVHDF.

Authors:  Joon Seok Choi; Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Seung Jung Kee; Young Jong Woo; Soo Wan Kim
Journal:  Intensive Care Med       Date:  2012-10-25       Impact factor: 17.440

Review 3.  Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature.

Authors:  Sherif Hanafy Mahmoud
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

4.  Successful treatment of severe carbamazepine toxicity with 5% albumin-enhanced continuous venovenous hemodialysis.

Authors:  Rajeev Narayan; Meagan Rizzo; Michael Cole
Journal:  J Artif Organs       Date:  2014-01-22       Impact factor: 1.731

5.  Overdose with antiepileptic drugs: the efficacy of extracorporeal removal techniques.

Authors:  Rita Moinho; Andrea Dias; Paula Estanqueiro; José Farela Neves
Journal:  BMJ Case Rep       Date:  2014-11-24

Review 6.  Pediatric renal replacement therapy in the intensive care unit.

Authors:  Brian C Bridges; David J Askenazi; Jessimene Smith; Stuart L Goldstein
Journal:  Blood Purif       Date:  2012-10-24       Impact factor: 2.614

7.  Lack of effect of high-volume continuous veno-venous haemofiltration with dialysis in massive carbamazepine overdose.

Authors:  Sachin Shah; Mark Tomlin; David Sparkes
Journal:  BMJ Case Rep       Date:  2012-10-12

8.  Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case report.

Authors:  Katherine L Collins; Eve A Roberts; Khosrow Adeli; Desmond Bohn; Elizabeth A Harvey
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

9.  Sequential use of hemoperfusion and single-pass albumin dialysis can safely reverse methotrexate nephrotoxicity.

Authors:  Winnie Kwai Yu Chan; Wun Fung Hui
Journal:  Pediatr Nephrol       Date:  2016-06-22       Impact factor: 3.714

Review 10.  Management of toxic ingestions with the use of renal replacement therapy.

Authors:  Timothy E Bunchman; Maria E Ferris
Journal:  Pediatr Nephrol       Date:  2010-10-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.